Iovance Biotherapeutics Inc

300 Rouse Blvd
Philadelphia, PA 19102

Main Contact: Mr. Frederick Vogt, PhD, Esq.

https://www.iovance.com/

Business Description:

Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was initially developed by Dr. Steven A. Rosenberg at the National Cancer Institute (NCI). In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology were reported by NCI to have achieved objective and complete response criteria, respectively.

Business Type:

Business Information:

• Established in 2007
• Middle Market Company
• Publicly Owned
• Member Since 2020